IDEXX Laboratories (IDXX)
(Delayed Data from NSDQ)
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$468.63 USD
-9.21 (-1.93%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $468.63 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
D Value A Growth C Momentum C VGM
Zacks News
IDEXX (IDXX) Enhances Fecal Dx Antigen Testing Platform
by Zacks Equity Research
IDEXX's (IDXX) Fecal Dx antigen testing detects the most prevalent and clinically relevant intestinal parasites in dogs and cats.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business.
Idexx (IDXX) Up 11.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
ALC or IDXX: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
ALC vs. IDXX: Which Stock Is the Better Value Option?
IDEXX's (IDXX) Upcoming Launch to Detect Canine Leishmaniosis
by Zacks Equity Research
IDEXX (IDXX) expands the SNAP franchise with a comprehensive solution for detecting canine leishmaniosis.
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX), backed by the strength of the CAG Diagnostics business and momentum in ProCyte One expansion.
Compared to Estimates, Idexx (IDXX) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
Although the revenue and EPS for Idexx (IDXX) give a sense of how its business performed in the quarter ended September 2023, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
IDEXX (IDXX) Q3 Earnings Top Estimates, '23 Sales View Down
by Zacks Equity Research
IDEXX (IDXX) delivers better-than-expected earnings in the third quarter of 2023.
MedTech Stocks' Q3 Earnings Due on Nov 1: IDXX, EXAS & More
by Urmimala Biswas
MedTech companies' third-quarter results are likely to reflect a year-over-year decline. Let's see how IDXX, EXAS, TNDM and NVST fare this time.
Idexx Laboratories (IDXX) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Idexx (IDXX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
IDEXX Laboratories (IDXX) to Post Q3 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) third-quarter 2023 results are expected to reflect an impressive performance of the CAG segment.
IART vs. IDXX: Which Stock Is the Better Value Option?
by Zacks Equity Research
IART vs. IDXX: Which Stock Is the Better Value Option?
AngioDynamics (ANGO) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
AngioDynamics (ANGO) registers strong revenue growth in the Med Tech business in first-quarter fiscal 2024.
Here's Why You Should Hold on to IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) on solid premium instrument placements and upbeat guidance.
Idexx (IDXX) Down 1.6% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Idexx (IDXX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Is SPDR S&P Health Care Equipment ETF (XHE) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for XHE
Should iShares Russell Mid-Cap Growth ETF (IWP) Be on Your Investing Radar?
by Zacks Equity Research
Style Box ETF report for IWP
Here's Why You Should Invest in IDEXX (IDXX) Stock Right Now
by Zacks Equity Research
Investors continue to be optimistic about IDEXX (IDXX) due to the CAG business and the company's execution of its growth strategy.
Should You Invest in the SPDR S&P Health Care Equipment ETF (XHE)?
by Zacks Equity Research
Sector ETF report for XHE
Select Medical (SEM) Q2 Earnings Meet, Revenues Rise Y/Y
by Zacks Equity Research
Select Medical's (SEM) Q2 results reflect solid segmental revenues, attributable to higher patient days and outpatient visits. Management projects adjusted EPS of $1.86-$2.03 for 2023.
Idexx (IDXX) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
by Zacks Equity Research
The headline numbers for Idexx (IDXX) give insight into how the company performed in the quarter ended June 2023, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
IDEXX (IDXX) Q2 Earnings and Revenues Beat Estimates, View Up
by Zacks Equity Research
IDEXX (IDXX) delivers better-than-expected earnings and revenues in the second quarter of 2023, backed by CAG Diagnostics' recurring revenue growth.
Idexx Laboratories (IDXX) Q2 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Idexx (IDXX) delivered earnings and revenue surprises of 9.88% and 1.70%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
IDEXX Laboratories (IDXX) to Post Q2 Earnings: What's in Store?
by Zacks Equity Research
IDEXX Laboratories' (IDXX) second-quarter 2023 results are expected to reflect an impressive performance in the CAG segment.
Idexx Laboratories (IDXX) is a Top-Ranked Momentum Stock: Should You Buy?
by Zacks Equity Research
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.